GLP-3 RT 10mg
Triple receptor metabolic research peptide
Questions About This Product?
Not sure if this is right for your research? Our team is here to help.
How It Works
GLP-3 RT works by simultaneously activating three important hormone receptors: GLP-1, GIP, and glucagon receptors, creating a comprehensive metabolic response that surpasses single-pathway approaches.
Triple-Receptor Activation
GLP-1 Receptor
Triggers insulin release when blood sugar is high, slows stomach emptying, and reduces appetite signals.
GIP Receptor
Enhances insulin response and influences fat metabolism pathways for improved metabolic efficiency.
Metabolic Research
Glucagon Receptor
Helps the body burn stored fat for energy and maintains healthy blood sugar levels between meals.
Synergistic Effect
The triple-action approach creates a comprehensive metabolic response more effective than single-pathway compounds in research settings.
Specifications
Research Findings
Preclinical and early clinical research on GLP-3 RT (Retatrutide) has demonstrated its potential as a triple receptor agonist across multiple metabolic research domains.
Weight Management Studies
Preclinical research has demonstrated significant weight reduction in laboratory models with dose-dependent effects and synergistic triple-receptor mechanisms.
- ▸ Significant weight reduction in laboratory models
- ▸ Dose-dependent effects with higher doses showing greater outcomes
- ▸ Synergistic effects surpassing single or dual-receptor agonists
- ▸ Sustained weight management over extended research periods
Metabolic Health Research
Laboratory investigations have revealed comprehensive improvements across multiple metabolic markers and pathways in research models.
- ▸ Enhanced glucose homeostasis and insulin sensitivity
- ▸ Improved lipid profiles in research models
- ▸ Reduced inflammatory markers
- ▸ Better energy expenditure patterns
Comparative Studies
When compared to other GLP-1 receptor agonists, GLP-3 RT has demonstrated superior outcomes in weight reduction and metabolic improvements in research settings.
- ▸ Superior weight reduction compared to single-receptor compounds
- ▸ Enhanced metabolic improvements beyond GLP-1 alone
- ▸ Addition of GIP and glucagon activation provides unique benefits
- ▸ Improved therapeutic potential in research settings
Storage Guidelines
Lyophilized peptides are stable at room temperature for several weeks when stored in a dry, sealed container away from light and moisture.
For extended storage, refrigeration (2–8°C) or freezing (−20°C) is recommended.
All products sold for research use only.
Recent Research (2024–2026)
Latest peer-reviewed publications on triple receptor agonists for laboratory research applications.
Triple Receptor Agonism in Obesity Pharmacotherapy
PMC, May 2025
Comprehensive review of novel triple receptor agonists targeting GLP-1, GIP, and glucagon receptors. Discusses mechanisms of action and potential research applications in metabolic studies.
View Publication →Retatrutide Phase 2 Trial: Dose-Dependent Weight Reduction
New England Journal of Medicine, 2023
Phase 2 randomized controlled trial demonstrating dose-dependent weight reduction with retatrutide (GLP-3 RT) in research participants. Key reference for researchers studying triple receptor agonism.
View Publication →GLP-1/GIP/Glucagon Triple Agonism: Mechanisms and Metabolic Effects
Nature Reviews Drug Discovery, 2024
In-depth review of the molecular pharmacology of triple receptor agonists, covering receptor binding, signal transduction, and downstream metabolic effects relevant to laboratory research.
View Publication →FOR RESEARCH USE ONLY. This product is intended solely for laboratory research purposes. It is not intended for human or animal consumption, nor for use as a drug, food additive, or household chemical. PepHQ, LLC makes no claims regarding therapeutic or medical applications. Researchers are responsible for compliance with all applicable laws and regulations.